부산대학교 도서관

Objective: To assess the associations between depot medroxyprogesterone acetate (DMPA) and endometrial cancer. Methods: This multicenter case–control study was conducted among tertiary hospitals in Thailand. Patients were women with endometrial cancer. Controls were women admitted for other conditions, matched for age within 5 years of the patients' age. The controls had to have no abnormal vaginal bleeding, history of hysterectomy, or cancers of the other organs. A standardized questionnaire was used to gather information. Conditional logistic regression was applied to calculate adjusted odds ratio (aORs) and 95% confidence intervals (CIs). Results: During 2015 to 2021, 378 patients and 1134 controls were included. Ever use of DMPA was associated with a 70% decreased overall risk of endometrial cancer (aOR, 0.30 [95% CI, 0.21–0.42]). Endometrial cancer risk declined by 3% (aOR, 0.97 [95% CI, 0.96–0.98]) for every 3 months of DMPA use. The magnitude of the decline in endometrial cancer risk did not vary appreciably by cancer subtypes (aOR, 0.26 [95% CI, 0.17–0.41] and 0.38 [95% CI, 0.22–0.65] for low‐grade and high‐grade tumors, respectively). Conclusions: Depot medroxyprogesterone acetate use was inversely associated with endometrial cancer risk in a duration‐dependent manner. This association was independent of cancer subtype. Synopsis: Depot medroxyprogesterone acetate use was independently associated with a reduced risk of endometrial cancer. [ABSTRACT FROM AUTHOR]